The Trials and Troubles of a
Symbolic Senator
Never before had Barbra Streisand and Goldie
Hawn held fund-raisers for the Cook County Recorder of Deeds. But 1992 was
the "Year of the Woman," and no one symbolized
it more than Carol Moseley-Braun. Angered by the rough treatment Anita
Hill had endured, Moseley-Braun set out to become the first
African-American woman in the U.S. Senate -- and did.
The day she took office, poet Gwendolyn Brooks exalted her as "a young giant." Moseley-Braun fanned the high expectations. "By my very presence," she pledged, "the U.S. Senate will change."
Yet halfway through her first term, Moseley-Braun has disappointed many of those who struggled to elect her. Mired in campaign debt, dogged by a federal audit of how she spent $6.7 million in 1992, Moseley-Braun is fast approaching a crisis.
With the audit hanging over her, she can't persuade contributors to pay off the debt. Nor can she begin piling up the $10 million she'll need to run for re-election in 1998. Her harshest critics say these pressures have driven the senator into the arms of big business, and some former fans feel abandoned.
"I rarely hear Carol mentioned anymore," says Lu Palmer of Chicago's Black Independent Political Organization and a member of Moseley-Braun's '92 steering committee. "It's almost as if she's not there."
True, on core liberal issues such as welfare, the environment and affirmative action, the senator remains a passionate opponent of the Republican majority. But after three years in the Senate, she has learned the mercenary reality of Washington: if you want to stick around, you often have to check your ideals at the fund-raiser's door.
Moseley-Braun's financial problems leave
her vulnerable to that charge. Her campaign debt is $563,000, second
highest among senators facing re-election in 1998. In part that's
because she has had to pay $200,000 to lawyers and accountants
who are trying to placate the
Federal Election Commission.
Within weeks, Newsweek has learned, the FEC may disclose the results of a two-year audit of Moseley-Braun's chaotic '92 campaign, which was run by her fiance at the time, Kgosie Matthews.
She could be fined; she will almost certainly be embarrassed. Sloppy record-keeping has complicated the investigation. So far, she has filed 42 amendments -- one of them 1,347 pages long -- to her campaign report. Aides say their response was slowed when a power surge wiped lists of donors and expenses off a computer.
The fear of fallout from the FEC probe has spooked some potential donors. "There's a sense in the business community that she's a one-term senator," says Denis O'Toole, head of government relations at Household International, an Illinois-based credit company, whose political arm has given her $10,000.
Moseley-Braun dismisses the notion she's been compromised. "If I'm in bed with big business and I've still got this debt," she told Newsweek, "something's wrong, right?" Still, she has alienated old allies: It's not unusual for public-interest lobbies to sour on liberal senators who don't faithfully toe the line.
But the scorn reserved for Moseley-Braun is startling. "The bottom line is she's a corporatist," says Joseph Belluck, a lawyer with Congress Watch, a consumer group. Among her alleged sins: votes this year that would cap punitive damage awards to victims of defective products. Moseley-Braun sided with big business despite intense lobbying from consumer advocates -- and a personal plea from the then president of the NAACP.
She also cosponsored a bill that would make it harder for investors to sue executives who give overly rosy projections of a company's financial prospects; critics call it the "Crooks and Swindlers Protection Act."
Moseley-Braun counters that her priority is creating jobs -- something businesses can't do if huge damage awards undercut them. Elderly groups charge that Moseley-Braun went out of her way to defend the profits of a British drug company that has given her money.
Her ongoing fight to protect Glaxo Wellcome's patent on the ulcer drug Zantac has prevented U.S. companies from selling a generic equivalent at half the price. Her ties to the corporation are strong: she accepted $10,000 from Glaxo Wellcome's political arm, took $15,000 more for a speech and flew to a fund-raiser in a company jet. The Zantac issue is worth $3.6 billion to Glaxo Wellcome.
Moseley-Braun acknowledges her long friendship with a top executive of the firm, but says she supports helping drug companies seeking costly cures for diseases like AIDS.
In Illinois, some African-Americans are disturbed with Moseley-Braun. One lightning rod: her fawning support last year for the re-election of Chicago Mayor Richard M. Daley over two black progressives who had backed her run for the Senate. Her move was widely viewed as a play for Daley's well-heeled business supporters.
"Here's a black thought -- we put you in, don't leave us behind," says Hermene Hartman, publisher of Chicago's N'DIGO magazine and a longtime friend of Moseley-Braun. "Folks would have understood a party-line endorsement, but did she have to say she'd bake cookies for Daley?"
Hartman, who cosponsored a fund-raiser for Moseley-Braun in 1992, no longer contributes money. The senator says she regrets the cookie remark, but endorsed Daley because he was best for Chicago.
Moseley-Braun's pro-business votes on NAFTA and product liability have irritated labor officials. Now she's been warned that unless she cleans up her campaign finances, what's left of her labor support is at risk.
"We don't want to see her
embarrassed," says Dennis Gannon of the Chicago Federation of Labor.
"And we don't want to be embarrassed either."
Moseley-Braun says she carries heavy debts "because I'm not a
multimillionaire" able to finance campaigns out of her own pocket.
"Others of my colleagues... can go
under the mattress and pay it off."
Moseley-Braun is trying to fight back. In recent months she has led a campaign against "crumbling schools," urging that Congress fund repairs. "I'm forging a position in the moral center of the debates here in Washington," she says.
As a first-term Democrat, she has few chances to broker deals. But she can electrify the Senate, as she did during her '93 attack on Sen. Jesse Helms's attempt to renew the patent on a Dixie group's Confederate insignia.
Re-creating the magic of her last
campaign will be more difficult. It's too early to know who will run
against Moseley-Braun in 1998. But she already
has two tough opponents: debt and disillusionment.